Inogen Inc. (NASDAQ:INGN) has earned an average rating of “Buy” from the six ratings firms that are covering the firm. Three equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $58.50.
A number of brokerages have recently commented on INGN. Needham & Company LLC reaffirmed a “strong-buy” rating and set a $64.00 price target (up previously from $58.00) on shares of Inogen in a research report on Sunday, August 7th. JPMorgan Chase & Co. boosted their price objective on Inogen from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 5th. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, August 9th. Finally, Stifel Nicolaus lowered Inogen from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. They noted that the move was a valuation call.
Shares of Inogen (NASDAQ:INGN) opened at 66.08 on Tuesday. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 93.07 and a beta of 0.99. The stock’s 50 day moving average price is $59.14 and its 200-day moving average price is $54.39. Inogen has a 52 week low of $28.81 and a 52 week high of $67.78.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, November 3rd. The medical technology company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.03. Inogen had a return on equity of 9.59% and a net margin of 7.70%. The firm had revenue of $54.42 million for the quarter, compared to analysts’ expectations of $47.89 million. During the same quarter in the prior year, the firm earned $0.13 EPS. The business’s revenue for the quarter was up 33.5% compared to the same quarter last year. Equities analysts predict that Inogen will post $0.62 earnings per share for the current year.
In other Inogen news, VP Byron Myers sold 6,200 shares of the company’s stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $60.04, for a total value of $372,248.00. Following the transaction, the vice president now directly owns 41,385 shares in the company, valued at approximately $2,484,755.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Raymond Huggenberger sold 7,089 shares of the company’s stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $56.24, for a total value of $398,685.36. Following the completion of the transaction, the chief executive officer now owns 8,342 shares in the company, valued at $469,154.08. The disclosure for this sale can be found here. 5.18% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in shares of Inogen by 13.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 271,740 shares of the medical technology company’s stock worth $16,277,000 after buying an additional 32,400 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Inogen during the third quarter worth $658,000. Bamco Inc. NY raised its position in shares of Inogen by 33.3% in the third quarter. Bamco Inc. NY now owns 16,000 shares of the medical technology company’s stock worth $958,000 after buying an additional 4,000 shares in the last quarter. Gerstein Fisher acquired a new position in shares of Inogen during the third quarter worth $227,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Inogen during the third quarter worth $670,000.